Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer

Table 3 Univariate and multivariate Cox proportional hazards regression analyses of the clinicopathological parameters

	Univariate			Multivariate
	p value	HR	95% CI	p value	HR	95% CI
Age, years (≥50 vs. < 50)	0.73	0.89	0.47–1.68
Pre-NAC clinical stage (stage I and II vs. stage III)	< 0.01	3.1	1.58–5.81	< 0.01	2.17	1.57–7.27
ER (positive vs. negative)	0.97	1.1	0.48–2.14
HER2 (positive vs. negative)	0.012	0.3	0.11–0.77	0.016	0.28	0.10–0.79
ΔPNI (high vs. low)	0.018	2.2	1.14–4.41	0.042	2.17	1.08–4.76
ΔAlb (high vs. low)	0.058	1.9	0.97–3.52
ΔBMI (high vs. low)	0.66	0.87	0.45–1.63
ΔNLR (high vs. low)	0.66	1.2	0.61–2.18
Histological type (IDC vs. ILC or special type)	0.23	2.4	0.58–10.03
Pathological response to NAC (non-pCR vs. pCR)	0.19	0.64	0.32–1.25

ER Estrogen receptor, HER-2 Human epidermal growth factor receptor type 2, BMI Body mass index, NLR Neutrophil/lymphocyte ratio, PNI Prognostic nutritional index, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, NAC Neoadjuvant chemotherapy, pCR Pathological complete response

ISSN: 1471-2407